A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...
Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy. MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at leas ...
Trade Name: Tasigna® 150 mg Product Name: Tasigna Product Code: AMN107 INN or Proposed INN: nilotinib Product Name: Nilotinib 50 mg Product Code: AMN107 INN or Proposed INN: nilotinib Trade Name: Tasigna®150 mg Product Name: Tasigna Product Code: AMN107 INN or Proposed INN: nilotinib Pro ...
Novartis Pharma Services AG
NULL
Not Recruiting
Female: yes Male: yes
55
United States;Hungary;Canada;Singapore;Germany;Switzerland;Italy;Korea, Republic of
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH) A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH) A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...
Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy. MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at leas ...
Trade Name: Tasigna® Product Name: Tasigna Product Code: AMN107 INN or Proposed INN: nilotinib Product Name: nilotinib Product Code: AMN107 INN or Proposed INN: nilotinib Product Name: Nilotinib Product Code: AMN107 INN or Proposed INN: nilotinib Trade Name: Tasigna® Product Name: Tasigna Product Code: AMN107 INN or Proposed INN: nilotinib Product N ...
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial ...
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH) A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability a ...
Pulmonary Arterial Hypertension
Drug: Nilotinib;Drug: Placebo to nilotinib
Novartis Pharmaceuticals
NULL
Terminated
18 Years
N/A
All
23
Phase 2
United States;Canada;Germany;Korea, Republic of;Singapore;Switzerland;Hungary;Italy